Study claims cervical cancer vaccine economically viable
Research by GlaxoSmithKline found it would work out cheaper for the State to pay €345 per vaccine than to fund the €10.3 million it costs to diagnose and treat cervical cancer annually.
The results of the study will be presented at a meeting of the International Society of Pharmacoeconomics and Outcomes Research in Dublin today. A separate study is also being carried out for the Government by the National Centre for Pharmacoeconomics.
